UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2015

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation)

001-37487 (Commission File Number) 13-3632859 (IRS Employer Identification Number)

9635 Granite Ridge Drive, Suite 100 San Diego, California (Address of principal executive offices) 92123 (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by us from time to time with the Securities and Exchange Commission contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. When used in such filings, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to us or our management identify forward-looking statements. Such statements reflect our current view with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to our industry, our operations and results of operations and any businesses that we may acquire. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On September 25, 2015, Aethlon Medical, Inc. ("we") entered into an extension of our contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. We originally entered into the initial contract on September 30, 2011. DARPA entered into this contract extension in order to exercise its option to continue the contract for year five, the final year of the contract.

The DARPA contract is priced on a fixed-price basis. Pursuant to the contract extension, we have the potential to earn up to \$581,157 in fixed payments upon our achievement of the milestones for year five of the contract.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS

EXHIBIT NO. DESCRIPTION

10.1 DARPA Contract Extension dated September 25, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: <u>/s/ James B. Frakes</u> James B. Frakes Chief Financial Officer

Dated: September 28, 2015

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

10.1 DARPA Contract Extension dated September 25, 2015

AMENDMENT OF SOLICIT	TATION/MODE	PICATION OF CONTRACT		1. CONTRACT ID COD	DE.	PAGE OF PAGE	
AMENDMENT OF SOLICI	IATION/MODA	election of contract		J		1 3	
AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUISITION/PURCHASE REQ. NO.		5.PR0	DJECTN	O.(Ifapplicable)	
P00012	28-Sep-2015	SEE SCHEOULE					
ISSUED BY CODE	N66001	7. ADMINISTERED BY (Ifother than item 6)		CODE	S0514	A	
SPAWAR SYSTEMS CENTER PACIFIC YAN BIEDERMANN CODE 22530 YAN BIEDERMANNOĞINAVY MIL SSS90 HULL STREET SAN DIEGO ÇA 92112-5001		DCMA SAN DIEGO 7675 DAGGET ST SUITE 200 SAN DIEGO CA 92111-2241		SCD; C			
NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) AETHLON MEDICAL INC DUNSW 054400055 8910 UNIVERSITY CTR UN STE 000 SAN DIEGO CA 92122-1027		State and Zip Code)		9A. AMENDMENT OF SOLICITATION NO			
			_	9B. DATED (SEE IT	9B. DATED (SEE ITEM 11)		
			х	10.A. MOD. OF CONTRACT/ORDER NO. N66001-11-C-4188			
VANA			v	10B. DATED (SEE I	TEM I	3)	
ODE 47A31	FACILITY CO		X	as cop as			
1	1. THISITEM ONLY	APPLIES TO AMENDMENTS OF SOLI	CIT		ot exten		
RECEIVED ATTHE PLACE DESIGNATED FOR REJECTION OF YOUR OFFER. If by virtue of this provided each telegram or letter makes reference to to 2. ACCOUNTING AND APPROPRIATION	s arrendment you desire to of he solicitation and this some	range an offer already submitted, such change may	beir	ade by telegramor letter,			
See Schedule							
		TO MODIFICATIONS OF CONTRACT ACT/ORDER NO. AS DESCRIBED IN IT					
A. THIS CHANGE ORDER IS ISSUED PUT CONTRACT ORDER NO. IN ITEM 10. B. THE ABOVE NUMBERED CONTRACT	Α.						
office, appropriation date, etc.) SET FO	RTH IN ITEM 14, PU	RSUANT TO THE AUTHORITY OF FA	R4	3,103(B).		1-7-6	
C. THIS SUPPLEMENT AL AGREEMENT Mutual Agreement of the Parties		PURSUANT TO AUTHORITY OF:					
D. OTHER (Specify type of modification a	nd authority)						
IMPORTANT: Contractor is not,	is required to s	ign this document and return 1	CC	pies to the issuing offic	œ.		
DESCRIPTION OF AMENDMENT/MOD where feasible.) Modification Control Number: biederm This modification exercises and fully funds	152724						
	14						
*							
acept as provided herein, all terms and conditions of the	W-18-11-11-11-11-11-11-11-11-11-11-11-11-				Tr.		
Rodiner S. Kenley.	President/P. I	JACOB WARD		EMAIL:	y ypc c	я риш)	
SB. CONTRACTOR/OFFEROR	ISC. DATE SIGN		RIC		160	DATE SIGNE	
(Signature of person authorized to sign)	- 9/25/15	BY (Signature of Contracting O	ffic	er)	2 !	5 Sep 2015	
APPROVED BY OIRM 11-84		30-105-01		STANDA Prescribe FAR (48	d by GS		

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by \$581,157.00 from \$5,354,839.00 to \$5,935,996.00.

SECTION B - SUPPLIES OR SERVICES AND PRICES

CLIN 0011

The option status has changed from Option to Option Exercised.

CLIN 0012

The option status has changed from Option to Option Exercised.

SUBCLIN 001101 is added as follows:

001101 Funding for Opt 4 MIPR# ACRN \$581,157.00

HR0011518340

SECTION E - INSPECTION AND ACCEPTANCE

The following Acceptance/Inspection Schedule was added for SUBCLIN 001101:

INSPECT AT INSPECT BY ACCEPT AT ACCEPT BY N/A N/A Government

SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by \$581,157.00 from \$5,354,839.00 to \$5,935,996.00.

SUBCLIN 001101:

Funding on SUBCLIN 001101 is initiated as follows:

ACRN: AH

CIN: 130021178700011

Acctng Data: 9715160400 1320 BDL TTT20 1 5BT01C OR EADARP A255HR001151 83400200020602115E00 012199

Increase: \$581,157.00 Total: \$581,157.00

(End of Summary of Changes)